BioCentury
ARTICLE | Clinical News

Belinostat: Phase II data

September 24, 2012 7:00 AM UTC

Top-line data from the open-label, international pivotal Phase II BELIEF (PXD101-CLN-19) trial in 129 patients with relapsed or refractory PTCL showed that once-daily IV belinostat met the primary endpoint of an ORR of >=20%. Topotarget said the data are being further analyzed and will be reported next quarter. The trial enrolled patients who failed >=1 systemic therapy to receive once-daily 1,000 mg/m 2 IV belinostat on days 1-5 of a 21-day cycle. ...